Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct–ligated rats and human hepatic cells
暂无分享,去创建一个
J. Boyer | S. Cai | A. Mennone | Hongwei He | Shi-Ying Cai
[1] Trong Nguyen,et al. Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms , 2010, Journal of Lipid Research.
[2] J. Dranoff,et al. Portal fibroblasts: Underappreciated mediators of biliary fibrosis , 2010, Hepatology.
[3] G. Gores,et al. Diagnosis and management of primary sclerosing cholangitis , 2010, Hepatology.
[4] K. Lindor,et al. Latest and Emerging Therapies for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis , 2010, Current gastroenterology reports.
[5] J. Boyer,et al. Mouse organic solute transporter α deficiency enhances renal excretion of bile acids and attenuates cholestasis , 2010, Hepatology.
[6] M. Trojanowska. Noncanonical transforming growth factor β signaling in scleroderma fibrosis , 2009, Current opinion in rheumatology.
[7] J. Chiang,et al. Bile acids: regulation of synthesis , 2009, Journal of Lipid Research.
[8] C. Steer,et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid , 2009, Journal of Lipid Research.
[9] A. Rosato,et al. Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds. , 2009, Endocrine, metabolic & immune disorders drug targets.
[10] T. Roskams,et al. Vinculin and cellular retinol-binding protein-1 are markers for quiescent and activated hepatic stellate cells in formalin-fixed paraffin embedded human liver , 2009, Histochemistry and Cell Biology.
[11] K. Lindor,et al. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. , 2008, Clinics in liver disease.
[12] F. Marra,et al. Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. , 2008, Molecular aspects of medicine.
[13] A. Befeler,et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis , 2007, Current gastroenterology reports.
[14] J. Reichrath,et al. Vitamins as hormones. , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[15] T. Pusl,et al. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. , 2006, World journal of gastroenterology.
[16] J. Boyer,et al. Mrp4−/− mice have an impaired cytoprotective response in obstructive cholestasis , 2006, Hepatology.
[17] G. Svegliati-Baroni,et al. Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. , 2005, Gastroenterology.
[18] S. Bellentani. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? , 2005, European journal of gastroenterology & hepatology.
[19] D. Schuppan,et al. Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids , 2004, Hepatology.
[20] M. Reiss,et al. Smads 2 and 3 are differentially activated by TGF-β in quiescent and activated hepatic stellate cells: Constitutive nuclear localization of Smads in activated cells is TGF-β independent , 2003 .
[21] F. Lammert,et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. , 2002, Gastroenterology.
[22] Jatinder Lamba,et al. Disrupted Bile Acid Homeostasis Reveals an Unexpected Interaction among Nuclear Hormone Receptors, Transporters, and Cytochrome P450* , 2001, The Journal of Biological Chemistry.
[23] D. Mangelsdorf,et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. , 2000, Science.
[24] H. Schnaper,et al. The transforming growth factor-βbgr/SMAD signaling pathway is present and functional in human mesangial cells , 1999 .
[25] W. Stetler-Stevenson,et al. Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.
[26] S. Milani,et al. Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. , 1993, Gastroenterology.
[27] H. Abboud,et al. Phenotypical modulation of liver fat-storing cells by retinoids. Influence on unstimulated and growth factor-induced cell proliferation. , 1992, Journal of hepatology.
[28] S. Friedman,et al. Isolated hepatic lipocytes and kupffer cells from normal human liver: Morphological and functional characteristics in primary culture , 1992, Hepatology.
[29] M. Kaplan,et al. Primary biliary cirrhosis , 1998, Hepatology.
[30] N. Davidson,et al. Retinoic acid modulates rat Ito cell proliferation, collagen, and transforming growth factor beta production. , 1990, The Journal of clinical investigation.
[31] 川田 一仁. Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis , 2010 .
[32] 久森 重夫. All-trans-retinoic acid ameliorates carbon tetrachloride-induced liver fibrosis in mice through modulating cytokine production , 2010 .
[33] Hui Wang 王 晖,et al. Effect of all-trans retinoic acid on liver fibrosis induced by common bile duct ligation in rats , 2008, Journal of Huazhong University of Science and Technology [Medical Sciences].
[34] M. Reiss,et al. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta ) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. , 2003, The Journal of biological chemistry.
[35] H. Schnaper,et al. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells. , 1999, Kidney international.
[36] K. Lazaridis,et al. Primary biliary cirrhosis , 1998, Springer Netherlands.